The Journal of Sexual Medicine
February 1, 2026
Hendrikus Knegtering, Thalia Herder, Nynke Boonstra et al.
Psychedelic-assisted therapy (PAT) is increasingly investigated as a treatment for depression, post-traumatic stress disorder (PTSD), and substance use disorder. In the United States (US) and European Union, esketamine has been approved for the treatment of depression, while psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) have received Breakthrough Therapy Designation in the US for...
Social Science & Medicine
February 1, 2026
Sarah Kratina, Carol Strike, Robert Schwartz et al.
Psychedelic substances are recognized for their potential to ease psychological suffering linked to end-of-life issues, yet policy remains restrictive. The wide range of both substances and therapeutic approaches used in end-of-life populations has not been adequately covered by reviews to date. To identify and learn from the variety that exists within the research on therapeutic psychedelic...
Neurologic Clinics
February 1, 2026
Mina Ansari, Sophie I Elliott, Sophie E Holmes et al.
1 citation
The development of novel, rapid-acting treatments and the resurgence of interest in the therapeutic potential of psychedelic-like compounds has stimulated excitement and enthusiasm within the pharmaceutical industry, and provided new hope for millions of individuals suffering with mental illness such as major depressive disorder and post-traumatic stress disorder. This review summarizes the...
Journal of Psychopharmacology
January 30, 2026
Veronica Magar, Marlena Robbins, Óscar Martín López Fernández Lobo Blanco et al.
1 citation
Indigenous Peoples have cultivated and protected natural psychoactive medicines through ceremony, kinship, and spiritual responsibility across generations, yet their long-standing contributions have often been marginalized through extractive research, commercialization, and policy exclusion. It is Indigenous communities that have stewarded and gained expertise working with psychoactive...
Journal of Clinical Psychopharmacology
January 12, 2026
Natia Horato, Felipe Dalvi-Garcia, Pablo E P Dutra et al.
1 citation
Treatment-resistant depression (TRD), a clinical subtype of major depressive disorder (MDD), is associated with greater severity and functional impairment, representing a significant challenge in psychiatric care. Recent studies suggest that the use of psychedelics can provide rapid and substantial improvement in the severity of depressive symptoms. Therefore, the aim of this systematic review...
Drug Design, Development and Therapy
2026
Fan Bu, Lan Qin, Zhengchi Lou et al.
Depressive disorders remain a major source of disability worldwide, and many patients do not achieve sustained remission despite the availability of multiple antidepressant options. Unmet needs are particularly evident in treatment-resistant depression (TRD) and bipolar depression, where delayed onset of action, incomplete response, relapse, residual functional impairment, and tolerability...
International Journal of Drug Policy
2026
Guy Simon, Nir Tadmor, Demian Halperin
2 citations
Psychedelics induce transformative experiences leading to lasting changes in attitudes and behaviour, with outcomes depending on both pharmacological factors and the context of the experience ('set and setting'), marking a paradigm shift in mental health treatment. As psychedelics transition from traditional contexts to clinical settings, tension emerges between authenticity and...
Substance use & addiction journal
2026
Olivia Marcus, Brian Rush
There is an increasing interest in the use of psychedelics for the treatment of substance use disorders (SUDs) and to improve overall health and wellbeing. We aimed to update and complement research syntheses that have focused only on results from clinical trials by synthesizing the research across diverse methods to discuss implications from a broad and multi-faceted literature. We conducted a...
Psychedelic Harm Reduction
2026
Ido Hartogsohn
13 citations
Set and setting is a fundamental concept in the field of psychedelic studies, denoting the crucial importance of context to determining the character and quality of experiences with psychedelics. This paper suggests a framework for thinking of set and setting and its relevance for psychedelic harm reduction. It discusses how “set,” the diverse factors related to an individual’s mindset, and...
Psychedelic Harm Reduction
2026
Michael Koslowski, Peter Gasser
6 citations
Psychedelic substances have gained recognition for their therapeutic potential, but they also present challenges, with individuals occasionally experiencing distressing episodes referred to as challenging experiences or, in the recreational setting, “bad trips”. Trial therapists and physicians, but also healthcare professionals in emergency rooms, need a comprehensive strategy to effectively...